News
COVID-19 rapid antigen test notified to BfArM
We are happy to announce that Vakzine Projekt Management GmbH (VPM) together with Grit Overseas Pte. Ltd. in Singapore successfully notified a COVID-19 rapid antigen test to the German Institute for Pharmaceuticals and Medical Products (BfArM).
"The DiagnoSure SARS-CoV-2 Antigen Rapid Test is now available and will get reimbursed by the health insurance upon prescription by a doctor.", says Oorvahsk F. Dastoor, Managing Director of Grit Overseas.
The test detects the viral N-protein and is therefore applicable for all virus mutants independent of mutations in their spike protein. This allows a reliable and fast detection of SARS-CoV-2 for everyone.
"We are proud to be involved to make an additional rapid antigen test accessible to the public in this COVID-19 pandemic", says Dr. Leander Grode, Managing Director of VPM. This is the first medicinal product VPM was involved in.
VPM & Training courses 2021
Also in 2021, VPM will continue to be present at various training events of Forum Institut Heidelberg and hold online seminars and lectures. Click here & get discount!
Update on priMe study
TB vaccine candidate being investigated to prevent TB infection in infants in Phase III priMe study. Read more!
First clinical center in South Africa initiated for a Pan-African phase III trial against tuberculosis
Vakzine Projekt Management GmbH (VPM) announces that the first clinical center in South Africa has been initiated in a large phase III trial (priMe) to assess the efficacy and safety of the novel TB vaccine – VPM1002 - in comparison with BCG in healthy newborn infants. The clinical centers in Tanzania, Uganda and Gabon will follow in the next weeks.
Press release on VPM's COVID-19 study published in "Neue Presse"
"MHH testet Corona-Impfstoff – besser als Biontech & Co.?" Read more!
First vaccinee enrolled in a large phase III trial against tuberculosis in a Pan-African setting
Vakzine Projekt Management GmbH (VPM) announces that the first participant has been enrolled in a large phase III trial to assess the efficacy and safety of the novel TB vaccine – VPM1002 - in comparison with BCG in healthy newborn infants. Read more!
Tdap study enters phase III
Following the successful completion of phase II part of the Tdap study (tetanus, diphtheria and pertussis) Tadeus, phase III part will commence this week, which will include adults, adolescents and children to test the safety and immunogenicity of this vaccine. Read more!
30 Million Euro Loan from the EIB for TB
VPM receives 30 Million Euro Funding from the European Investment Bank for VPM1002 tuberculosis vaccine development in Africa. Read more or Stream the ceremony!
Hope for the elderly in the corona pandemic
First participants receive VPM1002 in a late-stage phase III clinical trial in Germany. Read more!
SARS-CoV-2 study kicks off in Germany
First participant enrolled in Phase III clinical trial of VPM1002 focused on healthcare workers battling the COVID-19 pandemic. Read more!